This cooperation will facilitate joint research to investigate the effect of CF102 on hepatitis C virus (HCV) replication in hepatocytes and elucidate the molecular mechanisms underlying the antiviral activity of CF102. One agreement was signed with the Rabin Medical Center in Israel, while the other agreement was signed with the Center for Neurovirology and Cancer Biology at Philadelphia Temple University.
Can-Fite’s second pipeline drug, CF102, is currently being developed for the treatment of liver diseases. The company previously reported that preclinical studies have suggested that the drug is active against viral and autoimmune liver inflammation. CF102 was also found to trigger programmed cell death (apoptosis) of liver cancer cells.
Pnina Fishman, CEO of Can-Fite, said: “These cooperation agreements will substantially increase our current understanding of the antiviral activity of CF102.”